ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,842.91
0.11%
Dow Jones
42,518.28
0.52%
US Dollar vs MXN
20.50323
-0.06%
Brent Oil
79.445
-0.32%
Bitcoin
96,874.08
0.38%
Pepperstone
Advertisement
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. AcelRX Pharmaceuticals Inc (ACRX) Cotización

AcelRX Pharmaceuticals Inc

AcelRX Pharmaceuticals Inc (ACRX)

NASDAQ
0.86
0.00
(0.00%)
Cerrado 14 Enero 3:00PM
Delayed by 15 minutes
0.86
0.00
( 0.00% )
Pre Mercado: 6:00PM
Delayed by 15 minutes

Mejore su cartera: debates en tiempo real e ideas comerciales prácticas.

Premium

Estadísticas y detalles clave

Último Precio
0.86
Postura de Compra
0.861
Postura de Venta
0.89
Volume Operado de la Acción
-
0.00 Rango del Día 0.00
0.00 Rango de 52 semanas 0.00
Capitalización de Mercado [m]
14.579M
Precio Anterior
0.86
Precio de Apertura
-
Hora
Última hora de negociación
-
Volumen financiero
-
Precio Promedio Ponderado
-
Volumen promedio (3 m)
-
Acciones en circulación
16,952,000
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-0.53
Beneficio por acción (BPA)
-1.09
turnover
651k
Beneficio neto
-18.4M

Acerca de AcelRX Pharmaceuticals Inc

AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-... AcelRx Pharmaceuticals Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. Its product portfolio includes DSUVIA and Zalviso for Moderate-to-severe acute pain. The company's products under pipeline are ARX-02 and ARX-03. The majority of its revenue is generated from DSUVIA product sales in the United States. Mostrar más

Sector
Pharmaceutical Preparations
Industria
Pharmaceutical Preparations
Sitio web
talphera.com
Sede
Wilmington, Delaware, USA
Fundado
-

ACRX Últimas noticias

Más noticias

Form 4 - Statement of changes in beneficial ownership of securities

24 Junio 2024
Edgar (US Regulatory)

Form 8-K - Current report

24 Junio 2024
Edgar (US Regulatory)

Form ARS - Annual Report to Security Holders

29 Abril 2024
Edgar (US Regulatory)

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

29 Abril 2024
Edgar (US Regulatory)

Form DEF 14A - Other definitive proxy statements

29 Abril 2024
Edgar (US Regulatory)

Form 8-K - Current report

19 Abril 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

21 Marzo 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

15 Marzo 2024
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

12 Marzo 2024
Edgar (US Regulatory)

Form 8-K - Current report

09 Enero 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10000000CS
40000000CS
120000000CS
260000000CS
520000000CS
1560000000CS
2600000000CS

ACRX - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de AcelRX Pharmaceuticals?
El precio actual de las acciones de AcelRX Pharmaceuticals es US$ 0.86
¿Cuántas acciones de AcelRX Pharmaceuticals están en circulación?
AcelRX Pharmaceuticals tiene 16,952,000 acciones en circulación
¿Cuál es la capitalización de mercado de AcelRX Pharmaceuticals?
La capitalización de mercado de AcelRX Pharmaceuticals es USD 14.58M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de AcelRX Pharmaceuticals?
AcelRX Pharmaceuticals ha negociado en un rango de US$ 0.00 a US$ 0.00 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de AcelRX Pharmaceuticals?
El ratio precio/beneficio de AcelRX Pharmaceuticals es -0.53
¿Cuál es el ratio de efectivo a ventas de AcelRX Pharmaceuticals?
El ratio de efectivo a ventas de AcelRX Pharmaceuticals es 15.1
¿Cuál es la moneda de reporte de AcelRX Pharmaceuticals?
AcelRX Pharmaceuticals presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de AcelRX Pharmaceuticals?
El último ingresos anual de AcelRX Pharmaceuticals es USD 651k
¿Cuál es el último beneficio anual de AcelRX Pharmaceuticals?
El último beneficio anual de AcelRX Pharmaceuticals es USD -18.4M
¿Cuál es la dirección registrada de AcelRX Pharmaceuticals?
La dirección registrada de AcelRX Pharmaceuticals es 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808
¿Cuál es la dirección del sitio web de AcelRX Pharmaceuticals?
La dirección del sitio web de AcelRX Pharmaceuticals es talphera.com
¿En qué sector industrial opera AcelRX Pharmaceuticals?
AcelRX Pharmaceuticals opera en el sector PHARMACEUTICAL PREPARATIONS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
SGBXSafe and Green Holdings Corporation
US$ 1.24
(129.63%)
32.22M
SGDSafe and Green Development Corporation
US$ 3.90
(59.84%)
5.27M
HSDTHelius Medical Technologies Inc
US$ 0.975
(40.90%)
10.71M
DXRDaxor Corporation
US$ 11.83
(40.33%)
11
EOLSEvolus Inc
US$ 13.00
(37.28%)
2
DYNXDynamix Corporation
US$ 5.01
(-48.88%)
1
NESRNational Energy Services Reunited Corporation
US$ 5.11
(-41.47%)
4
KODKodiak Sciences Inc
US$ 5.00
(-34.21%)
111
EBMTEagle Bancorp Montana Inc
US$ 10.01
(-31.90%)
6
HTLMHomesToLife Ltd
US$ 5.20
(-31.13%)
201
SGBXSafe and Green Holdings Corporation
US$ 1.24
(129.63%)
32.22M
GCTKGlucoTrack Inc
US$ 0.0921
(-24.51%)
11.39M
HSDTHelius Medical Technologies Inc
US$ 0.975
(40.90%)
10.71M
WINTWindtree Therapeutics Inc
US$ 0.2353
(-5.84%)
9.82M
RIMEAlgorhythm Holdings Inc
US$ 0.0547
(-30.05%)
8.21M

Discusión

Ver feed completo
Lurker3 Lurker3 3 minutos hace
Do you j$ck off on nvdia as well?
CK
EnoughAlready! EnoughAlready! 6 minutos hace
I agree. Something is wrong with Schwab. They showed massive loses in my Acct even though I'm green. I spoke with one of their reps the night before to address the issue and asked if they are using my shares to cover and he chuckled and said, "Schwab doesn't do that BUT other firms do" Okay!
FMCC
Princess17 Princess17 7 minutos hace
Have you been there?
SLV
StayHumble StayHumble 7 minutos hace
💹wow 80-$99 INCOMING! 💹 UCLA💹Xerox|Mercedes|Santander|AbbeyRoadInst|Chatsworth|Ernst&Young|Omnisport|PinsentMasons
https://www.dbmmgroup.com/wp-content/uploads/2024/03/DBMM_Creds_Deck_2024_2.pdf
https://investorshub.advfn.com/uimage/uploads/2024/12/23/betnvDBMM
DBMM
FOOOL FOOOL 9 minutos hace
#me too. BTW: it is becoming very long list
LWLG
gt1217 gt1217 9 minutos hace
Where is the chartist? Why no chart now? Saying they are just posting charts without forming an opinion is complete BS. Why? Because he is not here charting like he does when it's trading sideways or in a downtrend. He loves watching people agonize about it going down. I have my opinions why but tha
XRPUSD
sab63090 sab63090 10 minutos hace
To a certain extent you are right, but I don't make those rules! It's easy to have the price have a zero plus tick to short!

Watch those mm's who I believe are nasty people and NOT even needed today with the technology available but I'm not "connected", they are!
AVXL
StayHumble StayHumble 10 minutos hace
wow💹100% Xpert SHORT interest💹Significant Evidence of SHORTS💹

"...greatest Show On Earth,,,,,,,,,,,"
https://cdn.vox-cdn.com/uploads/chorus_asset/file/8687957/tenor.gif
HMBL
Methinks Methinks 11 minutos hace
https://www.pymnts.com/fraud-prevention/2025/91-percent-of-mid-sized-firms-plan-to-expand-ap-automation-to-combat-fraud/
"the need for reliable security systems is crucial"
Wave - they are calling your name!
Edward Edward 13 minutos hace
I see nowhere did the company or JK get 1 million bucks in cash

Sure they did, Here it is 500k for VXIT and 500K for GSTC ,his other company for a total of $1million:

"Final Order against James Katzaroff, VirExit Technologies, Inc. and Globestar Therapeutics Corporation
GSTC VXIT
Methinks Methinks 13 minutos hace
https://www.computerweekly.com/microscope/opinion/Cybersecurity-myths-that-are-putting-businesses-at-risk
Use Wave to get rid of the risks.
BIOCHEMUP BIOCHEMUP 13 minutos hace
They did an offering. 
QBTS
Bubae Bubae 14 minutos hace
There have been so many agreements within the 526 pages of the regulation A offering that it is difficult to know how many shares are still waiting to get into the game. Despite the announcement in yesterday's press release the filing still isn't showing up on the OTC site or the SEC EDGARS. A good
RDAR
diggitydoodle diggitydoodle 14 minutos hace
Even with new reports, it's clear that Ihub self proclaimed experts...still just guess what's happening. They just see what they want to. Then preach it as fact. It's what they do.
GLTA!
RNVA!!$$?????????????????????
RNVA
Number sleven Number sleven 16 minutos hace
Kiwi,
https://www.biospace.com/press-releases/eyepoint-provides-company-update-and-anticipated-development-milestones-for-2025#:~:text=Positive%20interim%2016%2Dweek%20data,%2B8.9%20letters%20vs.%20baseline.
Sleven,
OCUL
SunshineSmiles SunshineSmiles 16 minutos hace
I wonder how the QB status is going. MONI
MONI
Methinks Methinks 17 minutos hace
https://www.computerweekly.com/opinion/What-they-dont-tell-you-about-cyber-tatacks-The-Emotional-Impact-on-Staff
Good point! Using Wave could relieve this, as well.
Moonboy1 Moonboy1 17 minutos hace
The only reason this stock hasn't kept up with Qubt and rgti is they havnt done an offering yet and people are just worried it's coming soon in my opinion.
QBTS
uranium-pinto-beans uranium-pinto-beans 18 minutos hace
TSLA
Tesla price target raised to $325 from $270 at Barclays
Barclays analyst Dan Levy raised the firm's price target on Tesla to $325 from $270 and keeps an Equal Weight rating on the shares. The firm sees "several key areas dominating the Tesla business focus" for 2025 - the retur
TSLA
capgain capgain 18 minutos hace
It's funny how nobody is responsible for anything anymore.
uranium-pinto-beans uranium-pinto-beans 19 minutos hace
FRPT
Freshpet remains a top pick into 2025 at DA Davidson
DA Davidson analyst Brian Holland says Freshpet remains the firm's top pick into 2025 with a Buy rating and $189 price target. "No news is good news" coming out of the ICR Conference for Freshpet, which is a "best in class" g
FRPT
uranium-pinto-beans uranium-pinto-beans 19 minutos hace
Freshpet remains a top pick into 2025 at DA Davidson
Moonboy1 Moonboy1 20 minutos hace
Microsoft CEO says you are wrong and that NVDA CEO is full of Sh--. His stock is on the verge of tanking
NVDA
navycmdr navycmdr 20 minutos hace
Ever wondered what the Hottest Stock for 2025 will be? Well @traderkylec has some thoughts about it and it is probably not what you would expect. CNBC is missing out on this money glitch j/k. Watch the video. Kyles cat approved it for the portfolio.

https://youtu.be/m-LaVbwVJ78?si=bYo
FNMA
chicks0123 chicks0123 21 minutos hace
Good morning CLNVers 
CLNV

Su Consulta Reciente

NASDAQ
ACRX
AcelRX Pharmaceuticals
TG
AXKF
AXA Rosenberg Equity Alpha
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2025 ADVFN PLC - Todos los derechos reservados